DNA

ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301

Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement…

1 year ago

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement…

1 year ago

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery…

1 year ago

23andMe Announces Mathew Knowles as New Brand Ambassador

Collaboration to help increase awareness of the power of genetic testing when it comes to learning about personal health risksSUNNYVALE,…

1 year ago

Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024

SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the…

1 year ago

Prenetics Announces Second Quarter 2024 Financial Results

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New…

1 year ago

Mass General Hospital researcher Gary Ruvkun honored with 2024 Nobel Prize

Physiology or Medicine Prize award honors discovery of small regulatory RNAsBoston, MA, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Media notice:…

1 year ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development…

1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated…

1 year ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of…

1 year ago